Abstract:Objective To investigate the effects of different doses of pituitary adenylate cyclase- activating polypeptide(PACAP)on the functional and morphological outcome in a mice model of Parkinson' s disease(PD)rendered by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP).Methods Male mice were treated with PACAP 0.02, 0.20 or 2.00 μg by iv bolus for 7 days after MPTP was administered, and were compared with the saline-treated mice.The immunohistochemistry and Western blot were used to detect the alterations of PD biomarker including tyrosine hydroxylase(TH), dopamine transporter(DAT)and vesicular monoamine transporter2(VAMT2).In addition, monoamine neurotransmitters in the striatum of mice were measured by the high performance liquid chromatography (HPLC).Results TH immunohistochemistry indicated that the number of TH-positive neurons in the substantia nigra was increased in all PACAP-treated mice(PACAP(0.02 μg/d)group was 93.33±4.87, F=85.85,P0.01)compared with the saline-treated mice.Western blot demonstrated the expression of TH, DAT and VMAT2 were significantly decreased in NS-treated mice compared with the normal mice.TH expression in all of PACAP treated groups was significantly increased compared with the NS treated group and the increase in TH was greatest in the 0.02 μg/d PACAP treated group(136.34±8.45,F=113.88 ,P 0.01), but the expression of DAT and VMAT2 demonstrated different reactions in PACAP-treated mice.The concentrations of striatal dopamine and its metabolite DOPAC compared to the normal mice were decreased significantly in NS treated-groups.Only PACAP-treated(0.02 μg/d)mice(1590.7±473.3 ,F=375.71, P0.01)minimized the reduction of DOPAC compared with the NS-treated mice(P0.05).Conclusion Intravenous injection of PACAP27 offers a therapeutical effect in the MPTP-induced PD mouse model which may not be directly associated with the expression levels of the monoamine transporters.

Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson’s Disease Mouse Model

Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's disease

Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model

Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinson's Disease Mouse Model.

Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson’s Disease Mice

CDNF overexpression prevents motor-cognitive dysfunction by intrastriatal CPP-based delivery system in a Parkinson's disease animal model

Therapeutic Efficacy Of Aav8-Mediated Intrastriatal Delivery Of Human Cerebral Dopamine Neurotrophic Factor In 6-Ohda-Induced Parkinsonian Rat Models With Different Disease Progression

Adjusting Vascular Permeability, Leukocyte Infiltration, and Microglial Cell Activation to Rescue Dopaminergic Neurons in Rodent Models of Parkinson's Disease

NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson's disease.

N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson’s Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF

Therapeutic Effect of Neuropeptide PACAP27 on Parkinson's Disease in Mice

Neuroprotective Effect of Acteoside Against MPTP-induced Mouse Model of Parkinsons Disease

Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy

Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism

Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway

Neuroprotective Effects of Pacap27 in Mice Model of Parkinson'S Disease Involved in the Modulation of K(Atp) Subunits and D2 Receptors in the Striatum

Achyranthes Bidentata Polypeptide Protects Dopaminergic Neurons from Apoptosis in Parkinson's Disease Models Both in Vitro and in Vivo

N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease

Tetramethylpyrazine Alleviated Cytokine Synthesis and Dopamine Deficit and Improved Motor Dysfunction in the Mice Model of Parkinson’s Disease

4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease

Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.